1-(pyrzin-2-yl)-1H-benzimidazole | 1043906-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(pyrzin-2-yl)-1H-benzimidazole
• 英文别名: 1-(pyrazin-2-yl)-1H-benzimidazole；1-pyrazin-2-ylbenzimidazole
• CAS: 1043906-07-5
• 化学式: C₁₁H₈N₄
• mdl: MFCD18807619
• 分子量: 196.211
• InChiKey: YRROQKXUMUZBHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(pyrzin-2-yl)-1H-benzimidazole 在 silver carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 32.0h， 生成 10-propyl-5,10-dihydro-11H-benzo[b]pyrazino[2,3-e][1,4]diazepin-11-one
  参考文献：
  名称：

  通过苯并咪唑盐的开环/开环合成苯并二氮杂s

  摘要：

  吡咯并苯并二氮杂derivatives衍生物无疑是市售药物和候选药物中最重要的结构图案之一。构造苯二氮杂卓环衍生物的通常合成方法是基于两个高度官能化的合成子的缩合反应。然而，这些化合物的合成发展受到区域选择性和原子经济性的阻碍。在这项工作中，通过苯并咪唑盐的连续开环水解和分子内CH键的活化，一步一步合成了吡啶-苯并二氮杂backbone骨架及其类似物。通过控制实验和密度泛函理论（DFT）计算来探索反应机理。

  DOI：

  10.1002/chem.201905828
• 作为产物：
  描述：

  2-氯吡嗪 、 苯并咪唑 在 copper(l) iodide 、 N-(乙酰氨基-苯基-甲基)乙酰胺 、 sodium methylate 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以66%的产率得到1-(pyrzin-2-yl)-1H-benzimidazole
  参考文献：
  名称：

  N,N′-(Phenylmethylene)diacetamide Analogues as Economical and Efficient Ligands in Copper-Catalyzed Arylation of Aromatic Nitrogen-Containing Heterocycles

  摘要：

  N,N′-(苯亚甲基)二乙酰胺类似物是通过醛与酰胺或尿素的缩合反应简单制备而成的，发现其在铜催化的芳基卤化物与各种杂环核苷酸的偶联反应中是有效的配体。新开发的配体在该转化过程中显示了广泛的应用范围。包括咪唑、苯并咪唑、呋喃、吲哚和苯并三唑等化合物成功地与多样化的芳香卤化物发生芳基化反应，得到相应的产物，产率中等到优秀。

  DOI：

  10.1055/s-0028-1087350

文献信息

• PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20170183329A1

  公开（公告）日：2017-06-29

  The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, X, Y, and Z are each as defined in the specification:

  本公开提供了新颖的化合物或其盐，或者该化合物或盐的晶体，其抑制Axl并在治疗由Axl高功能引起的疾病、与Axl高功能相关的疾病的治疗和/或涉及Axl高功能的疾病的治疗中有用。本公开提供了具有以下式（I）所代表的四氢吡喃基甲基基团的吡啶酮衍生物，具有各种取代基，或其盐，或化合物或盐的晶体，其中R1、R2、R3、R4、R5、W、X、Y和Z均如规范中定义的。
• Pyridone Derivatives
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20130281428A1

  公开（公告）日：2013-10-24

  Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R 1 , R 2 , R 3 , R 5 , R 6 , A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided.

  提供了抑制Axl并用于治疗由Axl高功能引起的疾病、与Axl高功能相关的疾病和/或伴随Axl高功能的疾病的新型化合物或其盐，或其晶体。提供了由式（1）所代表的吡啶酮衍生物，具有各种取代基或其盐，或其晶体（其中式（1）中的R1、R2、R3、R5、R6、A、W、X和n分别如规范中定义）。
• Sequential Metal-CatalyzedN-Heteroarylation and C–C Cross-Coupling Reactions: An Expedient Route to Tris(hetero)aryl Systems
  作者：Jamie S. Siddle、Andrei S. Batsanov、Martin R. Bryce

  DOI：10.1002/ejoc.200800018

  日期：2008.6

  1-methylbenzimidazolone, imidazole and pyrrole. The products of these reactions then undergo palladium-catalyzed C–C cross-couplings with aryl or heteroarylboronic acids under Suzuki–Miyaura conditions to provide a rapid entry, from readily-available reagents, into tris(hetero)aryl scaffolds comprising two or three N-heterocyclic rings. The sequential N–C and C–C couplings can be performed in a one-pot process (two

  本文描述了铜催化的苯并咪唑、1-甲基苯并咪唑酮、咪唑和吡咯的 N-C 杂芳基化反应。然后，这些反应的产物在 Suzuki-Miyaura 条件下与芳基或杂芳基硼酸进行钯催化的 C-C 交叉偶联，以提供从容易获得的试剂快速进入包含两个或三个 N 的三（杂）芳基支架-杂环。连续的 N-C 和 C-C 偶联可以在一锅法中进行（给出了两个例子：>50% 的总产率）。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
• PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3168219A1

  公开（公告）日：2017-05-17

  It is intended to provide a novel compound or a salt thereof, or crystals of the compound or the salt, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. [Solution] The present invention provides a pyridone derivative having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or a salt thereof, or crystals of the compound or the salt (wherein R1, R2, R3, R4, R5, W, X, Y, and Z are each as defined in the specification).

  本发明旨在提供一种新型化合物或其盐，或该化合物或其盐的结晶，该化合物或其盐可抑制 Axl，并可用于治疗由 Axl 功能亢进引起的疾病、治疗与 Axl 功能亢进相关的疾病和/或治疗涉及 Axl 功能亢进的疾病。 [解决方案］ 本发明提供一种吡啶酮衍生物，该衍生物具有下式（I）所代表的具有各种取代基的四氢吡喃甲基，或其盐，或该化合物或该盐的结晶（其中R1、R2、R3、R4、R5、W、X、Y和Z各自如说明书中所定义）。
• Pyridone derivatives having tetrahydropyranylmethyl groups
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10442797B2

  公开（公告）日：2019-10-15

  The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R1, R2, R3, R4, R5, W, X, Y, and Z are each as defined in the specification:

  本公开提供了新型化合物或其盐，或化合物或其盐的结晶，它们抑制Axl，可用于治疗由Axl功能亢进引起的疾病、治疗与Axl功能亢进相关的疾病和/或治疗涉及Axl功能亢进的疾病。 本公开提供了具有下式(I)所代表的具有各种取代基的四氢吡喃甲基的吡啶酮衍生物，或其盐，或化合物或其盐的结晶，其中R1、R2、R3、R4、R5、W、X、Y和Z各自如说明书中所定义：